63 jili.com

63 jili.com SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Micron Technology, Inc. - MUAIC: Identities will not be released yet

Robots Are Taking Over. The Future of Elderly Care Is Being Transformed.

Clubs from across the football pyramid are “alarmed” by the lack of consultation on legislation which could “fundamentally affect the future of English football”, West Ham vice-chairwoman Karren Brady has said. The Apprentice star also argued that a lack of clarity from the Government on the ownership test is causing “significant uncertainty” for potential investors. This came as the House of Lords continued its scrutiny of the Football Governance Bill, which seeks to establish an independent regulator for the top five tiers of the men’s game. In the upper chamber, Baroness Brady said: “We are creating legislation which will profoundly affect 160 quite unique institutions, from Premier League clubs through to the National League community clubs, but it is important for everyone to understand that the consultation with these affected businesses by the current Government has been remarkably limited, almost unbelievably so. “Just seven Premier League clubs, I was one of them, was granted a brief half-hour meeting with the Secretary of State over the summer. “And following this cursory engagement, significant decisions were made that could fundamentally affect the future of English football, most notably with the inclusion of parachute payments within the backstop mechanism. “This is particularly concerning given that fundamental issues still remained unresolved, we still lack any clarity on Uefa’s position on state interference, for example, this clearly creates profound uncertainty for clubs competing in or aspiring to European competition, as well as our national teams.” “We don’t know what the ownership test will look like, this causes significant uncertainty for potential investors as to whether they are able to own a club,” she added. Lady Brady continued: “I have spoken to many of my colleagues across all of the football pyramid, we are all alarmed about and puzzled by the lack of discussion on the Bill with ministers. “Would the minister agree that we all want to get the detail of this Bill right? And can she see any downsides to providing meaningful opportunities to hear from all clubs across the football pyramid affected by the legislation?” Prior to this, Tory shadow sports minister Lord Parkinson of Whitley Bay had tabled an amendment which he said would allow clubs to “make their views known on this legislation” by including specific competitions on the face of the Bill. Labour frontbencher Baroness Twycross told the upper chamber: “I don’t think the leagues are confused either on which leagues this legislation will apply to.” She added: “This power is both reasonable and the result of evidence-based consultation with all key stakeholders in the industry. “This power ensures that the competitions in scope can be amended in a timely manner and ensures the scope of the regime remains relevant.” The peer later said: “Over the past three years there have been countless opportunities for all affected and interested parties to make representations.” Lady Brady also raised concerns about the financial distribution backstop, which she said is “clearly designed as a mechanism to gain direct access to, and apportionate Premier League revenue, and no-one else’s”. “I might add the backstop will allow the IFR (Independent Football Regulator) to do this even if it was against the Premier League clubs’ will, or even without the clubs’ agreement, even if it was to have a detrimental effect on the clubs and the overall competition it removes revenue from,” she added. The backstop would allow the new IFR to intervene in the distribution of Premier League broadcast revenue down the leagues as a last resort. It could be triggered by the Premier League, English Football League (EFL) or National League to mediate the fair financial distribution of this revenue if they are not able to come to an agreement. Conservative peers later raised concerns over the cost implications to clubs of establishing the regulator, although they faced claims of “filibustering” – wasting time by making overlong speeches in a bid to delay progress. Watching opposition benches blatantly filibustering to destroy the Football Governance Bill is nothing short of sporting vandalism.Football is broken. Clubs are struggling. Now those seats have been lost, do they no longer care about likes of Reading or Southend? @FairGameUK — Niall Couper (@NiallCouper) December 4, 2024 Labour peer Lord Watson of Invergowrie questioned why Lord Parkinson was showing “confected outrage” at the Bill when the former culture minister would have been defending a similar proposal had the Tories remained in power. Lord Parkinson, in his reply, said: “We want to see this regulator established, we want to see it doing its work and doing so effectively, but we also see before us a Bill that is different because of the election that was called and the result that happened, and we’re interrogating particularly closely the changes that the Government have made to the Bill – of which there are many. “And we have more concerns on these benches than we did before the election from my colleagues behind me about the way we do it.” The Tory peer pointed to Labour frontbenchers fulfilling their duties to “properly scrutinise” then-government legislation when they were on the opposition benches. Lady Twycross, in an intervention, said: “While I agree that (Lord Parkinson) is correct that I would scrutinise legislation when I was sitting on those (opposition) benches, I have never sought to filibuster a Bill to which my party had committed, which my party had laid before Parliament, and intended to filibuster it to the point of getting us stuck in treacle.” Lord Parkinson replied: “That is not what we’re doing.” Niall Couper, chief executive of the campaign group Fair Game, wrote on social media site X: “Watching opposition benches blatantly filibustering to destroy the Football Governance Bill is nothing short of sporting vandalism.”Stock market today: Wall Street slips as the 'Magnificent 7' weighs down the marketTottenham Hotspur forward Brennan Johnson and Springboks flyhalf Manie Libbok have probably never met. They may not even have heard about one another. But they have something in common. Johnson and Libbok have suffered terrible abuse online this year, singled out by online bullies for their perceived failures on the pitch in their respective sporting codes. Welsh star Johnson recently deactivated his Instagram account following a barrage of abuse for his lack of goals and assists in a Spurs shirt, while Libbok was crucified following his missed penalty earlier this year in the Springboks' Test match against Los Pumas in Argentina. However, both seem to be coping with the online abuse just fine, as Johnson has returned to form for Spurs, while Libbok provided the spark in the Springboks' win over Argentina in the return match at the Mbombela Stadium, where the Boks ended up lifting the Rugby Championship. But not all sports people deal with criticism or abuse in the same way. Some athletes go through rough patches longer than others because it impacts their mental health, which in turn impacts their performance on the pitch or court. The advent of social media has changed the game for sports people, as it is another revenue stream. Influencer marketing is all the rage right now, and sports people are seen as ideal to showcase products and services. But by putting themselves out there, they also become a target for so-called "trolls" who now have direct access to their lives. And most times these fans cross the line, with ugly and personal comments. When asked about the trolling Johnson suffered, Spurs' manager Ange Postecoglou slammed fans who abuse players online, saying "I hate that it's normalised, but unfortunately that's the world we live in". "Criticism is one thing, exasperation at a game, you accept that. To sit down and write something abusive anonymously... say it in front of me, you'll get a punch on the nose, you won't do it again, mate. But they won't... John Goliath

Falcons QB Cousins is looking to avoid interceptions, have bounce-back game in Minnesota homecomingSunshine Gold dethrones Black Gold3 underrated (HBO) Max movies you should watch this weekend (December 27-29)

Job market jitters real for some mid-career Minnesotans and recent grads

US stocks surge to records on tech gains, Fed rate cut hopesWEST PALM BEACH, Fla. — An online spat between factions of Donald Trump's supporters over immigration and the tech industry threw internal divisions in his political movement into public display. The rift laid bare the tensions between the newest flank of Trump's movement — wealthy members of the tech world including billionaire Elon Musk and fellow entrepreneur Vivek Ramaswamy and their call for more highly skilled workers in their industry — and people in Trump's Make America Great Again base who championed his hard-line immigration policies. The debate touched off this week when Laura Loomer, a right-wing provocateur with a history of racist and conspiratorial comments, criticized Trump's selection of Sriram Krishnan as an adviser on artificial intelligence policy in his coming administration. Krishnan favors the ability to bring more skilled immigrants into the U.S. People are also reading... Loomer declared the stance to be "not America First policy" and said the tech executives who aligned themselves with Trump did so to enrich themselves. Much of the debate played out on the social media network X, which Musk owns. Loomer's comments sparked a back-and-forth with venture capitalist and former PayPal executive David Sacks, whom Trump tapped to be the "White House A.I. & Crypto Czar." Musk and Ramaswamy, whom Trump tasked with finding ways to cut the federal government, weighed in, defending the tech industry's need to bring in foreign workers. It bloomed into a larger debate with more figures from the hard-right weighing in about the need to hire U.S. workers, whether values in American culture can produce the best engineers, free speech on the internet, the newfound influence tech figures have in Trump's world and what his political movement stands for. Trump had not yet weighed in on the rift. His presidential transition team did not respond to questions about positions on visas for highly skilled workers or the debate between his supporters online. Instead, his team instead sent a link to a post on X by longtime adviser and immigration hard-liner Stephen Miller that was a transcript of a speech Trump gave in 2020 at Mount Rushmore in which he praised figures and moments from American history. Musk, the world's richest man who has grown close to the president-elect, was a central figure in the debate, not only for his stature in Trump's movement but his stance on the tech industry's hiring of foreign workers. Technology companies say H-1B visas for skilled workers, used by software engineers and others in the tech industry, are critical for hard-to-fill positions. Critics say they undercut U.S. citizens who could take those jobs. Some on the right called for the program to be eliminated, not expanded. Born in South Africa, Musk was once on an a H-1B visa himself and defended the industry's need to bring in foreign workers. "There is a permanent shortage of excellent engineering talent," he said in a post. "It is the fundamental limiting factor in Silicon Valley." Trump's own positions over the years reflected the divide in his movement. His tough immigration policies, including his pledge for a mass deportation, were central to his winning presidential campaign. He focused on immigrants who come into the U.S. illegally but he also sought curbs on legal immigration, including family-based visas. As a presidential candidate in 2016, Trump called the H-1B visa program "very bad" and "unfair" for U.S. workers. After he became president, Trump in 2017 issued a "Buy American and Hire American" executive order, which directed Cabinet members to suggest changes to ensure H-1B visas were awarded to the highest-paid or most-skilled applicants to protect American workers. Trump's businesses, however, hired foreign workers, including waiters and cooks at his Mar-a-Lago club, and his social media company behind his Truth Social app used the the H-1B program for highly skilled workers. During his 2024 campaign for president, Trump said immigrants in the country illegally are "poisoning the blood of our country" and promised to carry out the largest deportation operation in U.S. history. However, Trump told a podcast this year that he wants to give automatic green cards to foreign students who graduate from U.S. colleges. "I think you should get automatically, as part of your diploma, a green card to be able to stay in this country," he told the "All-In" podcast with people from the venture capital and technology world. Those comments came on the cusp of Trump's budding alliance with tech industry figures, but he did not make the idea a regular part of his campaign message or detail any plans to pursue such changes. Be the first to know Get local news delivered to your inbox!Faruqi & Faruqi Reminds Match Group Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 24, 2025 – MTCH

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page. If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet. FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted. The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Financial Highlights "Reflecting on 2024, Citius Oncology has achieved pivotal milestones that underscore our commitment to advancing cancer therapeutics," stated Leonard Mazur , Chairman and CEO of Citius Oncology. "The FDA's approval of LYMPHIR for the treatment of cutaneous T-cell lymphoma marks a significant advancement in providing new options for patients battling this challenging disease. It is the only targeted systemic therapy approved for CTCL patients since 2018 and the only therapy with a mechanism of action that targets the IL-2 receptor. Additionally, the successful merger forming Citius Oncology, now trading on Nasdaq under the ticker CTOR, strengthens our position in the oncology sector. We expect it to facilitate greater access to capital to fund LYMPHIR's launch and the Company's future growth. With a Phase I investigator-initiated clinical trial combining LYMPHIR with pembrolizumab demonstrating promising preliminary results, indicating potential for enhanced treatment efficacy in recurrent solid tumors, and preliminary results expected from a second investigator trial with CAR-T therapies in 2025, we remain excited about the potential of LYMPHIR as a combination immunotherapy." "These accomplishments reflect the dedication of our team and the trust of our investors. As we look ahead, we remain steadfast in our mission to develop innovative therapies that improve the lives of cancer patients worldwide," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Research and Development (R&D) Expenses R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 . The increase reflects development activities completed for the resubmission of the Biologics License Application of LYMPHIR in January 2024 , which were associated with the complete response letter remediation. General and Administrative (G&A) Expenses G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-commercial and commercial launch activities of LYMPHIR including market research, marketing, distribution and drug product reimbursement from health plans and payers. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $7.5 million as compared to $2.0 million for the prior year. The primary reason for the $5.5 million increase was due to the amounts being realized over 12 months in the year ended September 30, 2024 , as compared to three months post-plan adoption in the year ended September 30, 2023 . Net loss Net loss was $21.1 million , or ($0.31) per share for the year ended September 30, 2024 , compared to a net loss of $12.7 million , or ($0.19) per share for the year ended September 30, 2023 . The $8.5 million increase in net loss was primarily due to the increase in our operating expenses. About Citius Oncology, Inc. Citius Oncology specialty is a biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. In August 2024 , its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million , is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals. For more information, please visit www.citiusonc.com Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Oncology are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; risks related to research using our assets but conducted by third parties; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS ONCOLOGY, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 Current Assets: Cash and cash equivalents $ 112 $ — Inventory 8,268,766 — Prepaid expenses 2,700,000 7,734,895 Total Current Assets 10,968,878 7,734,895 Other Assets: In-process research and development 73,400,000 40,000,000 Total Other Assets 73,400,000 40,000,000 Total Assets $ 84,368,878 $ 47,734,895 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 3,711,622 $ 1,289,045 License payable 28,400,000 — Accrued expenses — 259,071 Due to related party 588,806 19,499,119 Total Current Liabilities 32,700,429 21,047,235 Deferred tax liability 1,728,000 1,152,000 Note payable to related party 3,800,111 — Total Liabilities 38,228,540 22,199,235 Stockholders' Equity: Preferred stock - $0.0001 par value; 10,000,000 shares authorized: no shares issued and outstanding — — Common stock - $0.0001 par value; 100,000,000; 71,552,402 and 67,500,000 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,155 6,750 Additional paid-in capital 85,411,771 43,658,750 Accumulated deficit (39,278,587) (18,129,840) Total Stockholders' Equity 46,140,339 25,535,660 Total Liabilities and Stockholders' Equity $ 84,368,878 $ 47,734,895 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 4,925,001 4,240,451 General and administrative 8,148,929 5,915,290 Stock-based compensation – general and administrative 7,498,817 1,965,500 Total Operating Expenses 20,572,747 12,121,241 Loss before Income Taxes (20,572,747) (12,121,241) Income tax expense 576,000 576,000 Net Loss $ (21,148,747) $ (12,697,241) Net Loss Per Share – Basic and Diluted $ (0.31) $ (0.19) Weighted Average Common Shares Outstanding – Basic and Diluted 68,053,607 67,500,000 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Cash Flows From Operating Activities: Net loss $ (21,148,747) $ (12,697,241) Adjustments to reconcile net loss to net cash provided by operating activities: Stock-based compensation expense 7,498,817 1,965,500 Deferred income tax expense 576,000 576,000 Changes in operating assets and liabilities: Inventory (2,133,871) - Prepaid expenses (1,100,000) (5,044,713) Accounts payable 2,422,577 1,196,734 Accrued expenses (259,071) (801,754) Due to related party 14,270,648 14,805,474 Net Cash Provided By Operating Activities 126,353 - Cash Flows From Investing Activities: License payment (5,000,000) - Net Cash Used In Investing Activities (5,000,000) - Cash Flows From Financing Activities: Cash contributed by parent 3,827,944 - Merger, net (2,754,296) - Proceeds from issuance of note payable to related party 3,800,111 - Net Cash Provided By Financing Activities 4,873,759 - Net Change in Cash and Cash Equivalents 112 - Cash and Cash Equivalents – Beginning of Year - - Cash and Cash Equivalents – End of Year $ 112 $ - Supplemental Disclosures of Cash Flow Information and Non-cash Activities: IPR&D Milestones included in License Payable $ 28,400,000 $